This page lists current opportunities from CIP.
The NCI's Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs. Check the Concepts Cleared at the NCI Board of Scientific Advisors Meeting web site for the earliest possible information about future initiatives.
Source: FOA page
This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.
Source: FOA Page
Huiming Zhang, Ph.D., NCI, Phone: 240-276-5979, (firstname.lastname@example.org)
Cheryl L. Marks, Ph.D., NCI, Phone: 240-276-6217 (email@example.com)
Richard V. Mazurchuk, Ph.D., NCI, Phone: 240-276-7126 (firstname.lastname@example.org)
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.
Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, , imaging platforms, QI methods, decision support software and informatics to populate the research resource.
Source: FOA Page
Houston Baker, Ph.D., NCI. Phone: 240-276-5908 (email@example.com)
Miguel Ossandon, M.S., NCI. Phone: 240-276-5714 (firstname.lastname@example.org)
Rao L. Divi, Ph.D., NCI. Phone: 240-276-6913 (email@example.com)
Tiffani Bailey Lash, Ph.D., NIBIB. Phone: 301-451-4778 (firstname.lastname@example.org)
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem. The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported systems, (b) next-generation systems, (c) quality assurance and quality control, (d) validation and correlation studies, (e) quantitative imaging, and (f) related research resources. Because applications should be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. In addition, innovation may be considered as delivery of a new capability to end users. The partnership on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their system to solve their chosen cancer problem. This FOA will support clinical trials that test functionality, optimize, and validate the performance of the proposed translational work. This FOA does not intend to support either actual commercial production or basic research projects that do not emphasize translation.
Lori A. Henderson, Ph.D., NCI, Phone: 240-276-5930, (email@example.com)
Frank I. Lin, M.D., NCI, Phone: 240-276-5932, (firstname.lastname@example.org)
Image-Guided Intervention [IGI] trials:
Keyvan Farahani, Ph.D., NCI, Phone: 240-276-5921, (email@example.com)
Radiation Therapy related trials:
Bhadrasain Vikram, M.D., NCI, Phone: 240-276-5690, (firstname.lastname@example.org)
EXPLANATORY NOTE: This is a new R01 grant-funded program announcement that supports Phase I/II clinical trials in imaging and IGI. Funds up to $500,000 in direct costs for a total project period of 2 or 3 years will be provided with a limit of $250,000 in direct costs in any single year. The previous R21 grant-funded program announcement referred to as PAR-14-013 has been terminated. Please see the FOA for explicit details including sections: (1) SF-424 (R&R) - Other Project Information and, (2) Application Review Information which highlights clinical trial protocol and background information requirements respectively.
Robert J. Nordstrom, Ph.D., Phone: 240-276-5934, Email: email@example.com
James A. Deye, Ph.D., Phone: 240-276-5690, Email: firstname.lastname@example.org
This Funding Opportunity Announcement (FOA) invites research project - cooperative agreement (U01) applications which are expected to enhance the value of quantitative imaging (QI) in clinical trials for prediction and/or measurement of response to cancer therapies. One avenue for this enhancement is to emphasize the development, optimization and validation of state-of-the-art QI methods and software tools for potential implementation in single site phase 1 or 2 clinical trials. The second avenue to enhance QI methods is to address the challenges of integrating existing and or new QI methods as required for multicenter phase 3 clinical trials. This may involve evaluation of a range of multimodal imaging approaches, harmonization of image data collection, analysis, display and clinical workflow methods across imaging platforms, or testing their performance across different cancer sites.
Because this validation process is complex, a single research program cannot be expected to complete every detail from initial tool development to final integration into clinical trials. Therefore, it is anticipated that these research goals will require multidisciplinary efforts. Although the involvement of industrial partners in the development of the QI methods is not required, it is strongly encouraged. Awardees will also join the Quantitative Imaging Network (QIN) to share ideas and approaches in order to validate and standardize imaging data and related imaging metadata for quantitative measurements of prediction and/or response to cancer therapies.
See the CIP QIN Website for a description of the program.
Houston Baker, Ph.D.; Phone: 240-276-5908; Email: email@example.com
Please see the FOA for a complete list of contacts.
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi-modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA may also include, as a secondary goal, support for other laboratory imaging or reference methods as required to validate the performance of the proposed in vivo imaging system and/or methods. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported imaging systems/methods, (b) next-generation imaging systems/methods, (c) quality assurance and quality control methods, (d) validation and correlation studies, (e) quantitative imaging methods, and (f) related research resources. Because appropriate applications must be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. The partnerships on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their proposed imaging system/methods to solve a targeted cancer problem. This FOA will support clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. This FOA will not support commercial production, or basic research projects that do not emphasize translational development and optimization of the methods for a targeted cancer problem.